NASDAQ
MRKR

Marker Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Marker Therapeutics Inc Stock Price

Vitals

Today's Low:
$5.6
Today's High:
$6.3
Open Price:
$6.3
52W Low:
$0.6706
52W High:
$9.68
Prev. Close:
$6.15
Volume:
104142

Company Statistics

Market Cap.:
$47.92 million
Book Value:
2.163
Revenue TTM:
$9.26 million
Operating Margin TTM:
-296.72%
Gross Profit TTM:
$-17125779
Profit Margin:
-142.92%
Return on Assets TTM:
-46.22%
Return on Equity TTM:
-115.8%

Company Profile

Marker Therapeutics Inc had its IPO on 2014-03-25 under the ticker symbol MRKR.

The company operates in the Healthcare sector and Biotechnology industry. Marker Therapeutics Inc has a staff strength of 67 employees.

Stock update

Shares of Marker Therapeutics Inc opened at $6.3 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.6 - $6.3, and closed at $5.77.

This is a -6.18% slip from the previous day's closing price.

A total volume of 104,142 shares were traded at the close of the day’s session.

In the last one week, shares of Marker Therapeutics Inc have increased by +6.07%.

Marker Therapeutics Inc's Key Ratios

Marker Therapeutics Inc has a market cap of $47.92 million, indicating a price to book ratio of 1.1336 and a price to sales ratio of 3.5926.

In the last 12-months Marker Therapeutics Inc’s revenue was $9.26 million with a gross profit of $-17125779 and an EBITDA of $-24194024. The EBITDA ratio measures Marker Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Marker Therapeutics Inc’s operating margin was -296.72% while its return on assets stood at -46.22% with a return of equity of -115.8%.

In Q2, Marker Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.5%.

Marker Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Marker Therapeutics Inc’s profitability.

Marker Therapeutics Inc stock is trading at a EV to sales ratio of 3.6408 and a EV to EBITDA ratio of -0.4721. Its price to sales ratio in the trailing 12-months stood at 3.5926.

Marker Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$21.96 million
Total Liabilities
$2.92 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Marker Therapeutics Inc ended 2024 with $21.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.96 million while shareholder equity stood at $19.03 million.

Marker Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $2.92 million in other current liabilities, 8799.00 in common stock, $-430500836.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.12 million and cash and short-term investments were $18.12 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Marker Therapeutics Inc’s total current assets stands at $21.96 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.75 million compared to accounts payable of $1.59 million and inventory worth $0.

In 2024, Marker Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Marker Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.77
52-Week High
$9.68
52-Week Low
$0.6706
Analyst Target Price
$40

Marker Therapeutics Inc stock is currently trading at $5.77 per share. It touched a 52-week high of $9.68 and a 52-week low of $9.68. Analysts tracking the stock have a 12-month average target price of $40.

Its 50-day moving average was $5.73 and 200-day moving average was $3.08 The short ratio stood at 0.99 indicating a short percent outstanding of 0%.

Around 1231.1% of the company’s stock are held by insiders while 2382.5% are held by institutions.

Frequently Asked Questions About Marker Therapeutics Inc

The stock symbol (also called stock or share ticker) of Marker Therapeutics Inc is MRKR

The IPO of Marker Therapeutics Inc took place on 2014-03-25

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$426.1
-1.25
-0.29%
$50.55
0.76
+1.53%
$49.81
-2.46
-4.71%
$74.69
-0.5
-0.67%
$2.41
0.01
+0.42%
$10.21
0.01
+0.1%
$58.33
-3.52
-5.69%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.

Address

3200 Southwest Freeway, Houston, TX, United States, 77027